Zacks Investment Research upgraded Nexvet Biopharma plc (NASDAQ:NVET) to Hold in a report released today.
- Updated: April 20, 2017
Zacks Investment Research has upgraded Nexvet Biopharma plc (NASDAQ:NVET) to Hold in a report released on Friday April 21, 2017.
Yesterday Nexvet Biopharma plc (NASDAQ:NVET) traded -0.30% lower at $6.60. The company’s 50-day moving average is $4.22 and its 200-day moving average is $3.93. The last closing price is up 67.90% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time. 128,600 shares of the stock were exchanged, up from an average trading volume of 65,764
See Chart Below
Nexvet Biopharma plc has a 52 week low of $2.61 and a 52 week high of $6.76 The company’s market cap is currently $0.
General Information About Nexvet Biopharma plc (NASDAQ:NVET)
Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company's platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal's immune system, a property referred to as 100% species-specificity. PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to create new therapies for companion animals. Biologics generally include mAbs, which are targeted antibodies derived from identical (clonal) cells. The Company's advanced product candidates are in pivotal-phase development: ranevetmab (or NV-01) and frunevetmab (or NV-02).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.